Astellas doesn't see eye to eye with Europe on geographic atrophy drug Izervay

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.